
Valley Fever is ready to slam California again with record-breaking cases: Here's what you need to know
The lung infections are caused by a fungus that grows in western soil, resulting in serious or long-term lung problems and potentially death if it is not treated and spreads to the brain. It results in thousands of cases every year in the U.S. and hundreds of deaths.
The Golden State, where Valley Fever was first discovered, is consistently the state with the most infections. After a record year, early state data shows it's on track for what is looking to be another big one. There are already more than 3,100 confirmed cases across the state.
That's more than there were at the same time last year and nearly double the amount in 2023.
'There is no question that the number of cases of coccidioidomycosis is enormously higher than before,' Dr. Royce Johnson, chief of the division of infectious disease and director of the Valley Fever Institute at Kern Medical in California, recently told NBC News. 'If you want to see me, right now you'd have to wait until July, and that goes for my colleagues, too.'
The majority of this year's cases are in Kern, Los Angeles, Monterey and Fresno counties. A significant oil-producing area, wildfire-stricken Kern has often been the epicenter of outbreaks — but there are new areas of concern. Cases in the East Bay's Contra Costa County have more than tripled since 2023. Merced has also seen cases steadily increase and San Bernardino has seen 60 more than last year.
'It appears to be spreading out,' Gail Sondermeyer Cooksey, an epidemiologist at the California Department of Public Health, told the network.
How do exposures occur?
Valley Fever, officially called coccidioidomycosis, was first discovered in Southern California's San Joaquin Valley.
The lung infection is caused by the fungus Coccidioides that grows in soil in western parts of the U.S., with the majority of cases reported in California and Arizona.
Valley Fever is caused by breathing in infectious spores, although some who are exposed are never infected. The spores can be kicked up during wind events, or through agricultural work and construction.
While people can get Valley Fever at any time of the year, they are more likely to be infected during late summer and fall. Cases typically peak between September and November, due to a delay from infection to reporting.
What's the concern?
Symptoms can include fatigue, cough, fever, headache, shortness of breath, night sweats, muscle aches, joint pain and a red rash on the upper body or legs. As many as 10 percent of those who are infected will develop serious or long-term problems in their lungs.
Another 1 percent will see it spread to their skin, bones, joints or brain.
Those older than 60 are more likely to be infected, as well as people who have weakened immune systems, are pregnant, have diabetes and people who are Black or Filipino.
People who work outdoors are also at a higher risk.
The climate connection
Researchers have found that cases of the disease spike in California during a shift from drought to heavy rainfall.
California specifically has seen rapid shifts from extreme drought to long-lasting atmospheric river events in recent years.
Wet winters can provide the ideal conditions for Valley Fever infections, as the summer dries out the land and breaks down the fungus into infectious spores.
After flooding and mudslides in March, the state is in for a hot and dry summer, according to federal forecasters.
'As climate change alters the timing and intensity of precipitation in California, we see longer high-risk periods for Coccidioides exposure,' Simon Camponuri, a PhD candidate at U.C. Berkeley, said in a statement.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Reuters
16 minutes ago
- Reuters
US FDA's top vaccine official Vinay Prasad leaves agency after short stint
July 29 (Reuters) - The U.S. Food and Drug Administration's top official, Vinay Prasad, has left the agency after nearly three months as Director of the Center for Biologics Evaluation and Research, a government spokesperson said late on Tuesday. Prasad, an oncologist who previously criticized the FDA and was a fierce critic of U.S. COVID-19 vaccine and mask mandates, had been appointed in May. "Dr. Prasad did not want to be a distraction to the great work of the FDA in the Trump administration and has decided to return to California and spend more time with his family," a spokesperson from the Department of Health and Human Services told Reuters in an emailed statement. Endpoints News first reported Prasad's departure. His exit comes after a number of unusual regulatory actions, including those taken recently by the agency on Sarepta Therapeutics'(SRPT.O), opens new tab gene therapy, Elevidys. "Unprecedentedly, there were multiple press leaks from the FDA, negatively impacting (its) credibility," said BMO Capital Markets analyst, Koustas Billouri. During Prasad's short stint, the U.S. FDA limited the use of COVID-19 vaccines and declined to approve therapies from Replimmune (REPL.O), opens new tab and Capricor Therapeutics (CAPR.O), opens new tab. The regulator's decisions under Prasad raised concerns that he was anti-patient choice, Jefferies analyst Roger Song said, adding that investors will see his departure as a positive for gene therapy and vaccine makers. The Nasdaq Biotechnology Index (.NBI), opens new tab declined 7% on Prasad's appointment, but has since recovered. Shares of Replimmune rose 58%, Sarepta was up 11.2% and Capricor added 21.2% in premarket trading on Wednesday. Prasad also held the additional role of the agency's chief medical and science officer, to which he was appointed last month, according to STAT News. Nominating a more seasoned official to replace him could help the FDA rebuild its credibility, BMO's Billouri said.


Reuters
16 minutes ago
- Reuters
Insurer Humana raises annual profit forecast as medical costs stabilize
July 30 (Reuters) - Humana (HUM.N), opens new tab raised its annual profit forecast on Wednesday, as the U.S. health insurer bets on its efforts to rein in higher medical costs that have plagued the sector, sending its shares up nearly 5% in premarket trading. The company is a top provider of Medicare Advantage plans under which the U.S. government pays private insurers a set rate to manage healthcare for people aged 65 and older, and those with disabilities. The industry has been battling with persistently high costs for the last two years due to increased use of healthcare services across government-backed plans. However, Humana said its medical costs were in line with its expectations. "We feel good about our solid performance in the first half of the year," CEO Jim Rechtin said in a statement. It reported a quarterly medical cost ratio - the percentage of premiums spent on medical care- of 89.7%, up from 88.9% a year earlier, but in line with analysts' estimates of 89.71%. The company said its quarterly performance was partly driven by better-than-expected membership in its individual Medicare Advantage (MA) plans, as well as strength in its primary care segment CenterWell. Humana expects membership decline in its MA plans to be lower than previously anticipated and said it remains confident that its insurance pricing will drive margin improvement. The company on Wednesday projected full-year profit to be about $17 per share, compared with its previous estimate of about $16.25. Analysts on average were expecting a profit of $16.38 per share, as per data compiled by LSEG. For the quarter, Humana earned a profit of $6.27 per share, compared to estimates of $5.92.


Reuters
an hour ago
- Reuters
Insurer Humana raises annual profit forecast, shares climb
July 30 (Reuters) - Humana (HUM.N), opens new tab raised its annual profit forecast on Wednesday, as the U.S. health insurer bets on its efforts to rein in higher medical costs that have plagued the sector, sending its shares up nearly 6% in premarket trading. The company is a top provider of Medicare Advantage plans under which the U.S. government pays private insurers a set rate to manage healthcare for people aged 65 and older, and those with disabilities. The industry has been battling with persistently high costs for the last two years due to increased use of healthcare services across the government-backed plans. However, Humana said its medical costs were in line with its expectations. It reported a quarterly medical cost ratio - the percentage of premiums spent on medical care- of 89.7%, up from 88.9% a year earlier, but in line with analysts' estimates of 89.71%. Humana now expects full-year profit to be about $17 per share, compared with its previous estimate of about $16.25. Analysts on average were expecting a profit of $16.38 per share.